ÂÜÀòÂÒÂ×

Richard DiMarchi, PhD, is one of the world’s leading peptide chemists, and has made key contributions to the biotech industry for 40 years as an academic, an inventor, an entrepreneur and a scientific executive.

Dr. DiMarchi is currently Distinguished Professor of Biochemistry and Gill Chair in Biomolecular Sciences at Indiana University and separately serves as Vice President of Research at Novo Nordisk Research Labs in metabolic diseases. He is a co-founder and director of Assembly Pharmaceuticals, a clinical-stage public biotech company focused on treatments for hepatitis B and microbiome-associated disorders. Previously, Dr. DiMarchi was a co-founder and director of biotechnology companies Ambrx and Marcadia Biotech; a founder and director of Calibrium; and a partner of Twilight Ventures. He also served as a director of Ionis and Millennium BioTherapeutics. At Eli Lilly, Dr. DiMarchi served as global leader of biotechnology and designed the first insulin analog, Humalog®. He also contributed to the commercial development of major pharmaceutical products such as Forteo®, Glucagon®, Evista®, Humatrope® and Humulin®. He is an inductee of the National Inventors Hall of Fame and the National Academy of Medicine. Dr. DiMarchi received a BS in Chemistry with honors from Florida Atlantic University and a PhD in Biochemistry from Indiana University. He completed a postdoctoral fellowship at The Rockefeller University with Bruce Merrifield.